Annoroad raised $100M in a Series C financing, led by SAIF Partners and joined by SBCVC, Shenzhen GTJA Investment Group and Ping An Ventures.
November 2, 2017 -- Annoroad, a Beijing genetics services company, raised $100 million in a Series C financing, led by SAIF Partners and joined by SBCVC, Shenzhen GTJA Investment Group and Ping An Ventures. Founded in 2012, Annoroad makes non-invasive prenatal diagnostic tests and also assists life science companies in their genetic research. The company has formed partnerships with Illumina for sequencing, Intel for precision medicine and AliCloud, for a cloud-based bioinformatics program called Solar Genomics.
